What You Need to Know
John Theurer Cancer Center will be the first in New Jersey, and one of just five cancer programs - across the globe to offer RefleXion®X1 - the world’s first machine to offer biology-guided radiotherapy (BgRT*). This may improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.
RefleXion’s BgRT, under review with the U.S. Food & Drug Administration, which you can see here, combines PET imaging with stereotactic radiotherapy to allow doctors to detect and respond to signals emitted from the cancer itself and use them to guide immediate treatment.
BgRT is designed to eliminate the need for delivering radiation to the entire internal target volume (ITV) by tracking the delivery of the radiation dose to the cancer cells live when the radiotherapy is occurring. By sparing more healthy tissue and reducing toxicity for the patient, this may allow for a higher dose to be delivered to the targeted tumor or may allow some of the radiation dose to be delivered elsewhere at the site of a different tumor.
The RefleXion X1 is currently approved for treating patients using conventional stereotactic body radiotherapy, intensity modulated radiation therapy and stereotactic radiosurgery. The BgRT feature is expected to receive approval from the U.S. Food and Drug Administration in 2022. The system will be installed at Hackensack University Medical Center in the fall of 2022.